Please Wait.....
Report
Brazil Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 78 Pages I Mordor Intelligence
Brazil Drug Delivery Devices Market Analysis
The Brazil drug delivery devices market size will reach USD 6.08 billion in 2025 and is forecast to attain USD 8.66 billion by 2030, reflecting a steady 7.32% CAGR. Expansion is underpinned by a large chronic-disease population, rapid adoption of connected care technologies, and a supportive industrial policy that targets 70% domestic supply of medical devices by 2033. Demand is strongest for injectable formats used in diabetes and biosimilar therapies, while implantable systems are gaining traction thanks to oncology advances and sustained-release convenience. A parallel boom in home-care and telehealth services is widening access to self-administered devices, even as tariffs and approval timelines lengthen time-to-market for sophisticated electronics. Multinationals still dominate innovation, yet local firms are scaling up under the Nova Industria Brasil program, improving cost competitiveness and resilience
Brazil Drug Delivery Devices Market Trends and Insights
Government Programs Popularizing Adoption of Biosimilar Self-Injection Therapies
National Biosimilar Drug Day, instituted for 16 December 2024, spotlights lower-cost biologics and boosts confidence among prescribers and payers. Sales jumped 43% in 2023 to 892,000 units, reinforcing patient familiarity with pen-style injectors. The Brazilian Society of Rheumatology's interchangeability consensus further validates switching, encouraging procurement bodies to specify self-injectable formats that facilitate out-of-hospital care and improve adherence.
Government Support for Domestic Manufacturing
Nova Industria Brasil channels BRL 300 billion in soft financing to help local firms meet 70% of national device demand by 2033. Medical-device exports surpassed USD 1 billion in early 2024, confirming capacity gains. ANVISA's June 2024 Reliance Programme fast-tracks registration of devices already cleared abroad, shrinking approval lags for innovators who assemble or finish products on Brazilian soil, and lowering currency risk for hospital buyers.
High Tariffs on Advanced Electronic Delivery Devices Elevating End-User Prices
The post-pandemic restoration of an 11.2% import duty raises landed costs for smart insulin pumps and IoT-enabled adherence tools, with industry association Abimo warning that tariff disputes threaten sector inflation. While domestic assembly offers relief, key electronic sub-components still cross borders, dampening immediate price reductions for patients.
Other drivers and restraints analyzed in the detailed report include:
Rapid Expansion of Health-Insurance Coverage / High Burden of Chronic Disease and Ageing Population / Complex Regulatory Environment and Barriers in Import /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Injectable devices command 44.78% of the Brazil drug delivery devices market, propelled by widespread diabetes self-management programs and fast adoption of biosimilar pens. Government-backed education and free-at-point-of-care distribution inside SUS keep volumes high. However, persistent price gaps between branded pens and potential generics limit uptake in lower-income municipalities. Implantables, though smaller, are accelerating at a 9.47% CAGR as oncologists and ophthalmologists adopt biodegradable reservoirs that maintain therapeutic levels for months, cutting clinic load and boosting patient satisfaction. Optical-segment breakthroughs such as the DDS-25G insert validated safety in Phase I, positioning ocular implants as credible treatment options. Transdermal patches and infusion pumps appeal to elderly cohorts wary of needles, while nasal devices gain niche traction for rescue therapies.
Brazil drug delivery devices market size for implantables is on course to widen its revenue share as hospital formularies recognise long-acting value, and domestic startups exploit policy incentives to scale polymer extrusion lines. Conversely, syringes and conventional pens face commoditisation pressure as local assemblers enter tenders with lower bids.
Injectables remain dominant with 54.56% share due to entrenched physician habits and fast systemic absorption. The Brazil drug delivery devices market share for injectables benefits from 52 approved biosimilars and 30 more under ANVISA review, keeping pipeline richness visible to investors. Novo Nordisk's GLP-1 franchise, supplied via pens and weekly autoinjectors, continues to set therapy benchmarks.
Oral-mucosal routes, projected at an 8.78% CAGR, circumvent hepatic first-pass metabolism and suit paediatric and geriatric populations who struggle with swallowing. Buccal films that release antihypertensive or migraine drugs in minutes attract formulators seeking differentiation. Transdermal patches carry anti-anginal or hormone molecules steadily, while intranasal sprays appeal for seizure clusters. Ocular routes, though niche, gain credibility from domestic R&D alliances that pair biodegradable polymers with anti-VEGF agents for macular diseases.
The Brazil Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps and More), Route of Administration (Injectable, Inhalational, Transdermal Patches and More), Application (Cancer, Cardiovascular, Diabetes and More), End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Beckton Dickinson / Pfizer / Novartis / Johnson&Johnson / Sanofi / GlaxoSmithKline / Teva Pharmaceutical Industries / Eurofarma Laboratorios S.A. / Eli Lilly and Company / Roche / AstraZeneca / Bayer / B. Braun / Gerresheimer / West Pharmaceutical Services / Medtronic / Insulet / Ypsomed / Baxter / Cipla / Fresenius /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Government Programs Popularizing Adoption of Biosimilar Self-Injection Therapies
4.2.2 Government Support for Domestic Manufacturing
4.2.3 Rapid Expansion of Health-Insurance Coverage
4.2.4 High Burden of Chronic Disease and Ageing Population
4.2.5 Rising Adoption of Tele-pharmacy & IoT-Enabled Adherence Platforms
4.2.6 Increasing Demand for Home Healthcare and Smart Drug Delivery Systems
4.3 Market Restraints
4.3.1 High Tariffs on Advanced Electronic Delivery Devices Elevating End-User Prices
4.3.2 Complex Regulatory Environment and Barriers in Import
4.3.3 Persistent Needlestick Injury Litigation Increasing Liability Costs
4.3.4 Supply Chain Disruptions for Raw Material such as medcial Plastics and Limited Cold-Chain Infrastructure
4.4 Value / Supply-Chain Analysis
4.5 Regulatory and Technological Outlook
4.6 Porter's Five Forces Analysis
4.6.1 Bargaining Power of Suppliers
4.6.2 Bargaining Power of Buyers
4.6.3 Threat of New Entrants
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Device Type
5.1.1 Injectable Delivery Devices
5.1.2 Inhalation Delivery Devices
5.1.3 Infusion Pumps
5.1.4 Transdermal Patches
5.1.5 Implantable Drug Delivery Systems
5.1.6 Ocular Inserts & Delivery Implants
5.1.7 Nasal & Buccal Delivery Devices
5.2 By Route of Administration
5.2.1 Injectable
5.2.2 Inhalation
5.2.3 Transdermal
5.2.4 Oral
5.2.5 Mucosal (Buccal & Sublingual)
5.2.6 Ocular
5.2.7 Nasal
5.3 By Application
5.3.1 Cancer
5.3.2 Cardiovascular
5.3.3 Diabetes
5.3.4 Infectious Diseases
5.3.5 Other Applications
5.4 By End User
5.4.1 Hospitals
5.4.2 Ambulatory Surgical Centers
5.4.3 Homecare Settings
5.4.4 Other End Users
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Becton, Dickinson and Company
6.4.2 Pfizer Inc.
6.4.3 Novartis AG
6.4.4 Johnson & Johnson
6.4.5 Sanofi
6.4.6 GSK plc
6.4.7 Teva Pharmaceutical Industries Ltd.
6.4.8 Eurofarma Laboratorios S.A.
6.4.9 Eli Lilly and Company
6.4.10 Roche Holding AG
6.4.11 AstraZeneca plc
6.4.12 Bayer AG
6.4.13 B. Braun
6.4.14 Gerresheimer AG
6.4.15 West Pharmaceutical Services, Inc.
6.4.16 Medtronic plc
6.4.17 Insulet Corporation
6.4.18 Ypsomed AG
6.4.19 Baxter International Inc.
6.4.20 Cipla Limited
6.4.21 Fresenius Kabi
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security